Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes...
Transcript of Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes...
![Page 1: Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes Stage IllC1 I ICI IllC2 IllC2 IllC2 Regional lyrnph nodes cannot be assessed No](https://reader036.fdocuments.co/reader036/viewer/2022070801/5f0268f07e708231d4042369/html5/thumbnails/1.jpg)
![Page 2: Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes Stage IllC1 I ICI IllC2 IllC2 IllC2 Regional lyrnph nodes cannot be assessed No](https://reader036.fdocuments.co/reader036/viewer/2022070801/5f0268f07e708231d4042369/html5/thumbnails/2.jpg)
Sessão Fuzilamento
Não e seguro o tratamento conservador no câncer de endométrio estadio I
![Page 3: Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes Stage IllC1 I ICI IllC2 IllC2 IllC2 Regional lyrnph nodes cannot be assessed No](https://reader036.fdocuments.co/reader036/viewer/2022070801/5f0268f07e708231d4042369/html5/thumbnails/3.jpg)
• Prof Dr Fabio F O Rodrigues• Médico Assistente Titular do Serviço de Oncoginecologia e Mastologia do
Instituto do Câncer Dr Arnaldo Vieira de Carvalho – SOGM – ICAVC
• Médico Titular do Departamento de Cirurgia Oncológica de Mama e Ginecologia da Beneficência Portuguesa de São Paulo
• Doutor em Medicina pela Faculdade de Ciências Médicas da Santa Casa de São Paulo
![Page 4: Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes Stage IllC1 I ICI IllC2 IllC2 IllC2 Regional lyrnph nodes cannot be assessed No](https://reader036.fdocuments.co/reader036/viewer/2022070801/5f0268f07e708231d4042369/html5/thumbnails/4.jpg)
![Page 5: Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes Stage IllC1 I ICI IllC2 IllC2 IllC2 Regional lyrnph nodes cannot be assessed No](https://reader036.fdocuments.co/reader036/viewer/2022070801/5f0268f07e708231d4042369/html5/thumbnails/5.jpg)
![Page 6: Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes Stage IllC1 I ICI IllC2 IllC2 IllC2 Regional lyrnph nodes cannot be assessed No](https://reader036.fdocuments.co/reader036/viewer/2022070801/5f0268f07e708231d4042369/html5/thumbnails/6.jpg)
![Page 7: Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes Stage IllC1 I ICI IllC2 IllC2 IllC2 Regional lyrnph nodes cannot be assessed No](https://reader036.fdocuments.co/reader036/viewer/2022070801/5f0268f07e708231d4042369/html5/thumbnails/7.jpg)
• Estadiamento é CIRÚRGICO.....
• Avaliação estimada por exames de imagem• RM contraste é o método de escolha :
• Sensibilidade invasão estromal 80-90%
• Sensibilidade invasão cervical 56-100%
• Avaliação estimada por exames séricos• Ca 125 > 40 U/mL – Sensibilidade de 78% e Especificidade de 81 % para
metástases linfonodais
O ESTUDO NEGATIVO NÃO ASSEGURA QUE OESTADIAMENTO CIRÚRGICO COMPLETO NÃO SEJANECESSÁRIO
![Page 8: Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes Stage IllC1 I ICI IllC2 IllC2 IllC2 Regional lyrnph nodes cannot be assessed No](https://reader036.fdocuments.co/reader036/viewer/2022070801/5f0268f07e708231d4042369/html5/thumbnails/8.jpg)
• Apenas cerca de 5 % das pacientes encontram-se na pré-menopausa
• Até 25% das pacientes <40 anos – Tumor sincrônico de ovário
• Sind Lynch
• 22% de pacientes apresentaram upstaging no cenário presumido de EC I !!!!
![Page 9: Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes Stage IllC1 I ICI IllC2 IllC2 IllC2 Regional lyrnph nodes cannot be assessed No](https://reader036.fdocuments.co/reader036/viewer/2022070801/5f0268f07e708231d4042369/html5/thumbnails/9.jpg)
• Opções de tratamento : progestágenos• AMP
• AM
• DIU com levonorgestrel
• Dose, tempo de duração, taxas de resposta são conflitantes 70-80%
• Resposta completa e duradoura – 50% das pacientes
• Taxas de recorrência 24-41% em 15-35 meses
• Ainda que altas, as taxas de cura não são comparáveis ao tratamento cirúrgico
• Taxas de gravidez 28 – 47%
![Page 10: Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes Stage IllC1 I ICI IllC2 IllC2 IllC2 Regional lyrnph nodes cannot be assessed No](https://reader036.fdocuments.co/reader036/viewer/2022070801/5f0268f07e708231d4042369/html5/thumbnails/10.jpg)
![Page 11: Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes Stage IllC1 I ICI IllC2 IllC2 IllC2 Regional lyrnph nodes cannot be assessed No](https://reader036.fdocuments.co/reader036/viewer/2022070801/5f0268f07e708231d4042369/html5/thumbnails/11.jpg)
OBRIGADO !!!!
![Page 12: Apresentação do PowerPoint - IWEVENTOS · N2/N2mi/N2a Any N Any N MO MO FIGO Regional Lymph Nodes Stage IllC1 I ICI IllC2 IllC2 IllC2 Regional lyrnph nodes cannot be assessed No](https://reader036.fdocuments.co/reader036/viewer/2022070801/5f0268f07e708231d4042369/html5/thumbnails/12.jpg)